These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33824865)

  • 1. TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell.
    Lei G; Liu S; Yang X; He C
    Can J Gastroenterol Hepatol; 2021; 2021():8870907. PubMed ID: 33824865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin.
    Almendro V; Ametller E; García-Recio S; Collazo O; Casas I; Augé JM; Maurel J; Gascón P
    PLoS One; 2009; 4(3):e4728. PubMed ID: 19266094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
    Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
    Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential regulation of MMP7 in colon cancer cells resistant and sensitive to oxaliplatin-induced cell death.
    Ametller E; García-Recio S; Pastor-Arroyo EM; Callejo G; Carbó N; Gascón P; Almendro V
    Cancer Biol Ther; 2011 Jan; 11(1):4-13. PubMed ID: 20980803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
    Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
    PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.
    Moser C; Lang SA; Kainz S; Gaumann A; Fichtner-Feigl S; Koehl GE; Schlitt HJ; Geissler EK; Stoeltzing O
    Mol Cancer Ther; 2007 Nov; 6(11):2868-78. PubMed ID: 18025273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. siRNA-mediated silencing of MDR1 reverses the resistance to oxaliplatin in SW480/OxR colon cancer cells.
    Montazami N; Kheir Andish M; Majidi J; Yousefi M; Yousefi B; Mohamadnejad L; Shanebandi D; Estiar MA; Khaze V; Mansoori B; Baghbani E; Baradaran B
    Cell Mol Biol (Noisy-le-grand); 2015 May; 61(2):98-103. PubMed ID: 26025411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquisition of anticancer drug resistance is partially associated with cancer stemness in human colon cancer cells.
    El Khoury F; Corcos L; Durand S; Simon B; Le Jossic-Corcos C
    Int J Oncol; 2016 Dec; 49(6):2558-2568. PubMed ID: 27748801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.
    Zhou H; Lin C; Zhang Y; Zhang X; Zhang C; Zhang P; Xie X; Ren Z
    Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28217977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kaempferol sensitizes cell proliferation inhibition in oxaliplatin-resistant colon cancer cells.
    Park J; Lee GE; An HJ; Lee CJ; Cho ES; Kang HC; Lee JY; Lee HS; Choi JS; Kim DJ; Choi JS; Cho YY
    Arch Pharm Res; 2021 Dec; 44(12):1091-1108. PubMed ID: 34750753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
    Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene and protein expression in the oxaliplatin-resistant HT29/L-OHP human colon cancer cell line.
    Xiang Z; Kang QJ; Xiang X
    Genet Mol Res; 2015 Sep; 14(3):11013-22. PubMed ID: 26400331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of tNOX expression through the ROS-p53-POU3F2 axis contributes to cellular responses against oxaliplatin in human colon cancer cells.
    Chen HY; Islam A; Yuan TM; Chen SW; Liu PF; Chueh PJ
    J Exp Clin Cancer Res; 2018 Jul; 37(1):161. PubMed ID: 30029680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-338-3p confers 5-fluorouracil resistance in p53 mutant colon cancer cells by targeting the mammalian target of rapamycin.
    Han J; Li J; Tang K; Zhang H; Guo B; Hou N; Huang C
    Exp Cell Res; 2017 Nov; 360(2):328-336. PubMed ID: 28928082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell lines.
    Tsofack SP; Garand C; Sereduk C; Chow D; Aziz M; Guay D; Yin HH; Lebel M
    Mol Cancer; 2011 Nov; 10():145. PubMed ID: 22118625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
    Boyer J; McLean EG; Aroori S; Wilson P; McCulla A; Carey PD; Longley DB; Johnston PG
    Clin Cancer Res; 2004 Mar; 10(6):2158-67. PubMed ID: 15041737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsa_circ_0079662 induces the resistance mechanism of the chemotherapy drug oxaliplatin through the TNF-α pathway in human colon cancer.
    Lai M; Liu G; Li R; Bai H; Zhao J; Xiao P; Mei J
    J Cell Mol Med; 2020 May; 24(9):5021-5027. PubMed ID: 32243061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P53‑microRNA interactions regulate the response of colorectal tumor cells to oxaliplatin under normoxic and hypoxic conditions.
    Zhang J; Li C; Sun L; Sun D; Zhao T
    Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37921068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [MiR-145 inhibits drug resistance to Oxaliplatin in colorectal cancer cells through regulating G protein coupled receptor 98].
    Fu Q; Cheng J; Zhang J; Zhang Y; Chen X; Xie J; Luo S
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 May; 20(5):566-570. PubMed ID: 28534337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
    Tentori L; Muzi A; Dorio AS; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):117-25. PubMed ID: 23636450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.